Lexpos News

The Department of Health and Social Care (DHSC) has today (19/08/2025) confirmed the following initial list of price concessions for August 2025: Drug Pack size Price concession Alfuzosin 2.5mg tablets 60 £7.22 Clarithromycin 250mg/5ml oral suspension 70 £10.52 Cyclizine 50mg/1ml solution for injection ampoules 5 £4.01 Dutasteride 500microgram capsules 30 £2.88 Ibuprofen 600mg tablets 84 £9.38 [...]

The post August 2025 Price Concessions 1st Update appeared first on Community Pharmacy England.

Pharmacy owners using the National Booking Service (NBS) to offer appointments for adult flu and COVID-19 vaccinations can now post appointments within the system, ahead of patients being able to use NBS to book appointments from 1st September 2025, for vaccination from 1st October 2025. The use of NBS for flu vaccinations is a voluntary [...]

The post Flu and COVID-19: NBS opens to post appointments appeared first on Community Pharmacy England.

On 12th August 2025 the Government and Lilly announced a health innovation programme of up to £85m, to be delivered by Innovate UK, to demonstrate new weight management pathways in the community. Through the programme, it is hoped that people living with obesity will be offered new types of holistic support to improve their health [...]

The post Obesity pathway innovation programme announced appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) Date issued: 14 August 2025 Drug Alert Number: EL(25)A/40 Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information. DMRC reference number: DMRC-35838218 Marketing Authorisation [...]

The post MHRA Class 4 Medicines Defect Notification: Levetiracetam 100mg/ml oral solution (Accord Healthcare Limited) appeared first on Community Pharmacy England.

Dapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff. This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga®. Currently, all branded and generically written prescriptions [...]

The post Dapagliflozin tablets – changes to reimbursement from September 2025 appeared first on Community Pharmacy England.